1 March 2025 in Journal of Pharmacology and Pharmacotherapeutics
Background: Pharmacogenomics aims to optimise drug therapy based on genetic makeup, but traditional clinical trial design faces challenges with complexity, cost and data integration. Purpose: This study explores integrating generative artificial intelligence (AI), specifically large language models (LLMs) like Llama3 8B, Mistral 7B v0.3 and Phi-3 Mini 3.8B, into pharmacogenomics clinical trial design through Retrieval-Augmented Generation frameworks and local knowledge bases to address the challenges. Materials and Methods: We conducted a comparative analysis of LLMs, evaluating the accuracy, relevancy, response time and operational efficiency with a case study that assessed LLMs’ capacity to address key trial design elements. The LLMs were locally run using an RTX 4080 mobile graphics card and Intel Core i9-13980HX central processing unit, with Open-WebUI employed. Results: Our results show that Llama3 8B and Phi-3 Mini 3.8B both achieved an accuracy and relevancy score of 0.92 and 0.89, showcasing their underscore of advanced capabilities in delivering both accurate and contextually relevant outputs. More thorough results showed that Phi-3 Mini 3.8B excelled in efficiency and scalability, while Llama3 8B provided greater contextual depth. Conclusion: This study indicates that generative AI offers transformative potential in pharmacogenomics clinical trials, enhancing efficiency and outcomes. However, challenges such as potential bias and the need for further validation remain. Addressing these limitations and advancing multimodal AI capabilities will further support inclusive and effective trial designs.
3 December 2025 in Asian Cardiovascular and Thoracic Annals
Introduction: Surgical revascularization through coronary artery bypass is a widely accepted approach for treating diseases affecting multiple coronary vessels. While the standard approach uses a single arterial graft combined with vein grafts, using numerous arterial grafts may improve long-term outcomes. Although supported by observational data and guideline recommendations, the broader adoption of multiple arterial grafting has been limited due to a lack of definitive randomized trial evidence and uncertainties in specific patient subgroups. Methods: A systematic review and meta-analysis were conducted to compare long-term survival in patients receiving multiple versus single arterial grafts during coronary artery bypass surgery. Twenty-seven studies (including one randomized trial) involving more than one million patients were included. The primary outcome was long-term all-cause mortality. Hazard ratios with 95% confidence intervals were pooled using a random-effects model. Subgroup analyses were performed based on age, sex, diabetes status, graft conduit type, extent of arterial revascularization, and left ventricular function. Meta-regression examined the impact of patient characteristics. Results: Multiple arterial grafting was associated with a significant reduction in long-term mortality compared to single arterial grafting. The pooled hazard ratio indicated an approximate 20% relative reduction in mortality. This survival benefit was consistent across all evaluated subgroups. Meta-regression did not identify any patient characteristic that significantly altered the benefit of multiple arterial grafting. No significant publication bias was detected. Conclusion: Multiple arterial grafting is associated with improved long-term survival in coronary artery bypass surgery. These findings support the broader implementation of this strategy in suitable patients while emphasizing the need for individualized surgical decision-making.